Goodwin represented Pieris Pharmaceuticals in its strategic collaboration with AstraZeneca to develop novel inhaled drugs that leverage Pieris’ Anticalin® platform. AstraZeneca will make an upfront and…
Pieris Pharmaceuticals and AstraZeneca Strike up to $2.1 Billion Collaboration on Anticalin-based Inhaled Treatments for Respiratory Diseases
